EMvision Medical Devices Ltd. (AU:EMV)
ASX:EMV
EMV Stock Chart & Stats
AU$1.77
-AU$0.06(-3.19%)
At close: 4:00 PM EST
AU$1.77
-AU$0.06(-3.19%)
Day’s Range― - ―
52-Week RangeAU$1.48 - AU$2.43
Previous CloseN/A
Volume36.00K
Average Volume (3M)120.98K
Market Cap
AU$145.91M
Enterprise ValueAU$127.28M
Total Cash (Recent Filing)AU$17.56M
Total Debt (Recent Filing)AU$4.02M
Price to Earnings (P/E)―
Beta0.68
Next Earnings
Sep 01, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.04
Shares Outstanding92,938,610
10 Day Avg. Volume127,185
30 Day Avg. Volume120,982
Financial Highlights & Ratios
PEG Ratio-0.07
Price to Book (P/B)16.01
Price to Sales (P/S)29.42
P/FCF Ratio-18.85
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$3.15Price Target Upside77.97% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.1
Revenue Forecast (FY)AU$6.00M
Bulls Say, Bears Say
Bulls Say
Addressable Market & Product FitEMvision’s focus on portable, rapid brain-imaging addresses a durable structural need in acute care and pre-hospital medicine. Over the next 2–6 months this positions the company to capture clinical adoption opportunities where decentralised, point-of-care diagnostics are increasingly prioritized by EMS and hospitals.
Moderate LeverageA debt-to-equity of 0.38 indicates conservative financial leverage, providing flexibility to fund ongoing R&D and commercialization without excessive interest burden. This balance supports medium-term resilience and reduces immediate refinancing pressure compared with highly leveraged peers.
High Gross Margin PotentialReported gross profit margin at 100% suggests low incremental product COGS and favorable unit economics. If revenue growth stabilizes, high gross margins can sustainably support investments in clinical studies and sales infrastructure while enabling path to positive operating leverage over time.
Bears Say
Declining RevenueA 37% revenue decline is a material, durable headwind that reduces scale and weakens adoption signals. Lower sales elevate per-unit fixed costs, compress operating leverage, and make it harder to demonstrate sustained clinical traction, threatening the commercialisation timeline and funding needs.
Negative Cash FlowsPersistent negative operating and free cash flows indicate ongoing cash burn and a shrinking runway unless financing occurs. This constrains the company’s ability to complete regulatory/clinical milestones, scale manufacturing, and invest in sales, increasing dependency on external capital or partnerships.
Persistent Losses & Capital EfficiencyNegative ROE reflects weak capital efficiency and persistent unprofitability. Over months this undermines investor confidence and limits access to non-dilutive financing, forcing trade-offs between accelerating commercialization and managing cash, until meaningful revenue or margin improvement occurs.
EMvision Medical Devices Ltd. News
EMV FAQ
What was EMvision Medical Devices Ltd.’s price range in the past 12 months?
EMvision Medical Devices Ltd. lowest share price was AU$1.48 and its highest was AU$2.43 in the past 12 months.
What is EMvision Medical Devices Ltd.’s market cap?
EMvision Medical Devices Ltd.’s market cap is AU$145.91M.
When is EMvision Medical Devices Ltd.’s upcoming earnings report date?
EMvision Medical Devices Ltd.’s upcoming earnings report date is Sep 01, 2026 which is in 146 days.
How were EMvision Medical Devices Ltd.’s earnings last quarter?
EMvision Medical Devices Ltd. released its earnings results on Feb 22, 2026. The company reported -AU$0.044 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.044.
Is EMvision Medical Devices Ltd. overvalued?
According to Wall Street analysts EMvision Medical Devices Ltd.’s price is currently Undervalued.
Does EMvision Medical Devices Ltd. pay dividends?
EMvision Medical Devices Ltd. does not currently pay dividends.
What is EMvision Medical Devices Ltd.’s EPS estimate?
EMvision Medical Devices Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does EMvision Medical Devices Ltd. have?
EMvision Medical Devices Ltd. has 92,938,610 shares outstanding.
What happened to EMvision Medical Devices Ltd.’s price movement after its last earnings report?
EMvision Medical Devices Ltd. reported an EPS of -AU$0.044 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of EMvision Medical Devices Ltd.?
Currently, no hedge funds are holding shares in AU:EMV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
EMvision Medical Devices Ltd. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
AU$3.15 (77.97% Upside)
AU$3.15 (77.97% Upside)
Blogger Sentiment
Bullish
AU:EMV Sentiment 100%
Sector Average 69%
Sector Average 69%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-5.44%
12-Months-Change
Fundamentals
Return on Equity
-70.29%
Trailing 12-Months
Asset Growth
25.56%
Trailing 12-Months
Company Description
EMvision Medical Devices Ltd.
EMvision Medical Devices Limited, a medical device company, engages in the research, development, and commercialization of imaging and diagnostic technology products. It develops a portable brain scanner for stroke diagnosis, monitoring, as well as other medical imaging needs. The company was incorporated in 2017 and is based in Macquarie Park, Australia.
EMV Stock 12 Month Forecast
Average Price Target
AU$3.15
▲(77.97% Upside)
Technical Analysis
Compumedics Limited
―
Impedimed Limited
―
Cyclopharm Limited
―
Aroa Biosurgery Ltd
―
4DMedical Ltd
―